NCT06011109View on ClinicalTrials.gov

Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 13, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

January 31, 2026

Conditions
GliomaGlioblastoma Multiforme
Interventions
DRUG

APG-157

The participants will receive APG-157 daily; and continue to receive Bevacizumab as standard of care.

Trial Locations (2)

55905

RECRUITING

Mayo Clinic, Rochester

68198

RECRUITING

University of Nebraska Medical Center, Omaha

Sponsors
All Listed Sponsors
lead

Aveta Biomics, Inc.

INDUSTRY

NCT06011109 - Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab | Biotech Hunter | Biotech Hunter